重组人血管内皮抑制素联合化疗对晚期乳腺癌疗效的Meta分析

冯林森; 李靖娟; 王羽丰

重组人血管内皮抑制素联合化疗对晚期乳腺癌疗效的Meta分析

1. 昆明医科大学第三附属医院暨云南省肿瘤医院
2. 昆明医科大学第一附属医院

基金项目:

基金：中国临床肿瘤学会科研基金资助项目 (Y-S2016-002); 云南省教育厅科学研究基金重点资助项目 (2015Z089);

计量
- 文章访问数: 1653
- HTML全文浏览量: 637
- PDF下载量: 76
- 被引次数: 0
出版历程
- 收稿日期: 2017-02-13

A Meta-analysis of rh-endostatin Combined with Chemotherapy in the Treatment of Advanced Breast Cancer

Funds:

基金：中国临床肿瘤学会科研基金资助项目 (Y-S2016-002); 云南省教育厅科学研究基金重点资助项目 (2015Z089);

摘要

摘要: 目的探讨重组人血管内皮抑制素 (rh-endostatin, rh-ES) 联合化疗对晚期乳腺癌的有效性与安全性.方法检索Pubmed、Embase、Cochrane Library、Spriner、中国知网、维普网、万方、CBM等数据库 (检索截止2016年04月) , 纳入研究对象为晚期乳腺癌患者, 以rh-ES联合化疗为治疗组, 以单纯化疗为对照组的随机对照研究, 采用Rev Man 5.3进行Meta分析, 比较两组的临床疗效与安全性.结果共纳入6篇文献, 包含346例病例, Meta分析结果显示Rh-ES+化疗组与单纯化疗组比较, 客观应答率 (RR=1.41, 95%CI:1.13~1.77) 、疾病控制率 (RR=1.21, 95%CI:1.08~1.35, P<0.01) 和疾病进展率 (RR=0.49, 95%CI:0.32~0.75) 差异有统计学意义.在安全性评估中, 两组白细胞减少、血小板减少及胃肠道反应发生率间均无统计学意义 (P>0.05) .结论 Rh-ES联用化疗方案治疗晚期乳腺癌可能提高客观反应率与疾病控制率, 减少疾病进展率, 对不良反应发生率无明显影响.
- 乳腺肿瘤 /
- 重组人血管内皮抑制素 /
- 有效性 /
- 安全性 /
- Meta分析
Abstract: Objective To evaluate the clinical efficacy and adverse effects induced by rh-endostatin (rh-ES) combined with chemotherapy in the treatment of advanced breast cancer. Methods The Pubmed, Embase, Cochrane Library, Spriner, CNKI, VIP, Wangfang Data, CBM were searched for literature up to April 2016. We searched randomized controlled clinical trials of rh-endostatin combined with chemotherapy in the treatment of advanced breast cancer and judged whether the trials met the inclusive criteria. Then Meta analysis was performed by using Rev Man v5.3 software after extracting useful data. Re s ults Six researches with 346 patients were included according to the inclusive criteria. Meta analysis demonstrated that rh-endostatin combined with chemotherapy had statistically significant increase over chemotherapy alone in terms of objective respond rate (RR=1.41, 95% CI: 1.13-1.77) or disease control rate (RR=1.21, 95% CI: 1.08-1.35) , and had statistically significant benefit in progression of disease ( RR=0.49, 95% CI: 0.32-0.75) . The incidence rates of leukopenia, thrombocytopenia and gastrointestinal reaction were no significant difference between two groups.Conclus ions Rh-endostatin combined with chemotherapy may have more meaningful clinical improvement in objective respond rate, disease control rate and progression of disease. The combination therapy had not added the adverse effects rates significantly.
- Breast neoplasms /
- Rh-endostatin /
- Clinical efficacy /
- Adverse effects /
- Meta analysis

HTML全文

参考文献(22)

[1]	[1]JAIN R K.Normalizing tumor microenvironment to treat cancer:bench to bedside to biomarkers[J].J Clin Oncol, 2013, 31 (17) :2205-18.
[2]	[2]HU B, ZHU H W, ZHU L P et al.Bioactivity, pharmacokinetics, and immunogenicity assays in preclinical and clinical trials for recombinant human endostatin[J].Acta Pharmacol Sin, 2008, 29 (11) :1357-69.
[3]	[3]PENG F, XU Z, WANG J, et al.Recombinant human endostatin normalizes tumor vasculature and enhances radiation response in xenografted human nasopharyngeal carcinoma models[J].PLo S One, 2012, 7 (4) :e34646.
[4]	[4]XU X, MAO W, CHEN Q et al.Endostar, a modified recombinant human endostatin, suppresses angiogenesis through inhibition of Wnt/beta-catenin signaling pathway[J].PLo S One, 2014, 9 (9) :e107463.
[5]	[5]MA X, YAO Y, YUAN D, et al.Recombinant human endostatin endostar suppresses angiogenesis and lymphangiogenesis of malignant pleural effusion in mice[J].PLo S One, 2012, 7 (12) :e53449.
[6]	[6]GUO Z Y, YAO G D, FU L P, et al.Effect of recombinant human endostatin on the expression of c-Myc and b FGF in mouse gastric cancer cells[J].Genet Mol Res, 2015, 14 (2) :5258-65.
[7]王金万, 孙燕, 刘永煜, 等.重组人血管内皮抑素联合NP方案治疗晚期NSCLC随机、双盲、对照、多中心Ⅲ期临床研究[J].中国肺癌杂志, 2005, 8 (4) :283-290.
[8]	[8]CHEN J, YAO Q, LI D et al.Neoadjuvant rh-endostatin, docetaxel and epirubicin for breast cancer:efficacy and safety in a prospective, randomized, phase II study[J].BMC Cancer, 2013, 13 (1) :248.
[9]陈俊民, 谢贤和, 刘华, 等.GN方案联合抗血管生成疗法治疗蒽环类及紫杉类治疗失败的晚期乳腺癌的临床研究[J].现代预防医学, 2010, 37 (14) :2767-2769.
[10]陆颖, 黄海欣, 李桂生.血管内皮抑素联合GP方案治疗转移性三阴性乳腺癌的临床研究[J].中国肿瘤临床, 2012, 39 (23) :1946-1948+1955.
[11]徐春凌, 梁栋.GP方案联合恩度治疗晚期转移性乳腺癌的临床疗效[J].中国实用医药, 2012, 7 (23) :131-132.
[12]夏欣欣, 韩黎丽, 李晓阳, 等.重组人血管内皮抑制素联合化疗治疗晚期乳腺癌疗效观察[J].中华实用诊断与治疗杂志, 2014, 28 (6) :621-622.
[13]张宁玲, 李秋梅.重组人血管内皮抑素联合吉西他滨顺铂方案治疗转移性三阴性乳腺癌的疗效观察[J].中国肿瘤临床与康复, 2014, 21 (4) :436-439.
[14]孙艳丽, 陈武, 陈飞.重组人血管内皮抑素联合化疗对晚期乳腺癌循环血管内皮细胞和血管内皮细胞生长因子的影响[J].中国医师杂志, 2015, 17 (5) :735-737.
[15]谷鸿秋, 王杨, 李卫.Cochrane偏倚风险评估工具在随机对照研究Meta分析中的应用[J].中国循环杂志, 2014, 29 (2) :147-148.
[16]曹德东, 戈伟, 王慧敏, 等.重组人血管内皮抑素联合化疗与单纯化疗在晚期非小细胞肺癌中疗效比较的系统评价[J].中国肺癌杂志, 2011, 14 (5) :404-413.
[17]侯晓雯, 时景璞, 陈欣.在Meta分析中如何利用中位数、极差和样本量估算均数、标准差[J].中国循证医学杂志, 2015, 15 (4) :484-487.
[18]周支瑞, 张天嵩, 李博, 等.生存曲线中Meta分析适宜数据的提取与转换[J].中国循证心血管医学杂志, 2014, 3 (1) :243-247.
[19]中国抗癌协会乳腺癌专业委员会.复发转移乳腺癌化学治疗基本原则[J].中华医学杂志, 2011, 91 (2) :73-75.
[20]覃晶, 张鹏海, 钱新宇, 等.重组人血管内皮抑素联合化疗心脏毒性的分析[J].中国肿瘤临床, 2008, 35 (1) :12-14.
[21]	[21]RONG B, YANG S, LI W, et al.Systematic review and meta-analysis of endostar (rh-endostatin) combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancer[J].World J Surg Oncol, 2012, 10 (1) :170.
[22]余婷婷, 徐细明, 陈彪.恩度联合GP方案治疗晚期非小细胞肺癌疗效及安全性的Meta分析[J].中华临床医师杂志 (电子版) , 2013, 7 (9) :3943-3946.